- Home
- SEE vs LEGN Comparison
SEE vs LEGN Comparison
Compare SEE & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEE
- LEGN
- Stock Information
- Founded
- SEE 1960
- LEGN 2014
- Country
- SEE United States
- LEGN United States
- Employees
- SEE N/A
- LEGN N/A
- Industry
- SEE Major Chemicals
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- SEE Industrials
- LEGN Health Care
- Exchange
- SEE Nasdaq
- LEGN Nasdaq
- Market Cap
- SEE 4.5B
- LEGN 5.4B
- IPO Year
- SEE N/A
- LEGN 2020
- Fundamental
- Price
- SEE $31.03
- LEGN $43.36
- Analyst Decision
- SEE Buy
- LEGN Strong Buy
- Analyst Count
- SEE 11
- LEGN 11
- Target Price
- SEE $38.18
- LEGN $74.60
- AVG Volume (30 Days)
- SEE 1.3M
- LEGN 1.5M
- Earning Date
- SEE 08-05-2025
- LEGN 08-08-2025
- Dividend Yield
- SEE 2.58%
- LEGN N/A
- EPS Growth
- SEE N/A
- LEGN N/A
- EPS
- SEE 2.02
- LEGN N/A
- Revenue
- SEE $5,335,500,000.00
- LEGN $728,303,000.00
- Revenue This Year
- SEE N/A
- LEGN $65.33
- Revenue Next Year
- SEE $2.33
- LEGN $54.68
- P/E Ratio
- SEE $15.06
- LEGN N/A
- Revenue Growth
- SEE N/A
- LEGN 112.46
- 52 Week Low
- SEE $22.78
- LEGN $27.34
- 52 Week High
- SEE $38.85
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- SEE 46.03
- LEGN 70.87
- Support Level
- SEE $30.42
- LEGN $38.53
- Resistance Level
- SEE $31.72
- LEGN $45.30
- Average True Range (ATR)
- SEE 0.68
- LEGN 1.72
- MACD
- SEE -0.09
- LEGN 0.35
- Stochastic Oscillator
- SEE 24.80
- LEGN 79.65
About SEE Sealed Air Corporation
Sealed Air is organized via two reporting segments. Food includes food packaging products like Cryovac, Darfresh, and OptiDure aimed primarily at meats. Protective includes Sealed Air's Bubble Wrap, Instapak, Jiffy mailers, and shrink film packaging systems that cater to industrial and e-commerce applications.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.